AGN. NO.

MOTION BY SUPERVISOR JANICE HAHN September 15, 2026

Proclaim November 24, 2026 as Antiphospholipid Syndrome Awareness Day

Antiphospholipid syndrome (APS) is a treatable autoimmune condition in which the body produces antiphospholipid antibodies (APLAs) that increase blood clots. During pregnancy these antibodies can raise the risk of miscarriage, stillbirth, and other complications. The National Institutes of Health (NIH) estimates that about six percent of pregnant patients test positive for APLAs, and APS accounts for roughly 15 percent of recurrent pregnancy losses. Because APS is not included in routine prenatal screening, the total number of miscarriages caused by APS remains unknown. Although not everyone with APLAs develops APS, there is a strong link between these antibodies and abnormal blood clotting.

Diagnosing APS is done with a simple blood test. An APS diagnosis can significantly affect pregnancy planning and individuals with APS require long-term management and regular medical follow-up, and women diagnosed with APS will need specialized guidance when preparing for pregnancy.

Current guidelines recommend testing for APS following an unexplained fetal loss after 10 weeks of pregnancy, or after three or more unexplained miscarriages (two miscarriages or one stillbirth). However, in practice the APS test does not always happen. But including a simple blood test for APS during routine prenatal screening could allow

MOTION

MITCHELL	_____
HORVATH	_____
HAHN	_____
BARGER	_____
SOLIS	_____

earlier detection and treatment with blood thinners.

A bipartisan house resolution, H. Res. 685[1], was introduced to raise awareness of this issue. The resolution supports adding APS testing to routine prenatal screenings and calls on medical associations and guideline-setting bodies to update recommendations to include testing for APS as a standard in prenatal screenings.

I, THEREFORE, MOVE that the Board of Supervisors proclaim November 24, 2026, as Antiphospholipid Syndrome Awareness Day in the County of Los Angeles, to help raise awareness and improve knowledge of antiphospholipid syndrome and the symptoms, causes and treatments of this rare autoimmune disease.

# # #

JH:cc

[1] BILLS-119hres685ih.pdf